The therapeutic potential of immune cell-derived exosomes as an alternative to adoptive cell transfer

키워드

참고문헌 (104)

1. Hinshaw DC, "the tumor microenvironment innately modulates cancer progression", Cancer Res, 79, pp.4557~4566 (2019)
2. Roma-Rodrigues C, "Targeting tumor microenvironment for cancer therapy", Int J Mol Sci, 20, pp.840~ (2019)
3. Baghban R, "Tumor microenvironment complexity and therapeutic implications at a glance", Cell Commun Signal, 18, pp.59~ (2020)
4. Yu Y, "Present and future of cancer immunotherapy : a tumor microenvironmental perspective", Oncol Lett, 16, pp.4105~4113 (2018)
5. Galluzzi L, "The hallmarks of successful anticancer immunotherapy", Sci Transl Med, 10, pp.eaat7807~ (2018)
6. Chuah S, "High-dimensional immuneprofiling in cancer : implications for immunotherapy", J Immunother Cancer, 8, pp.e000363~ (2020)
7. Disis ML, "Mechanism of action of immunotherapy", Semin Oncol, 41(Suppl 5), pp.S3~S13 (2014)
8. Houot R, "T-cell-based immunotherapy : adoptive cell transfer and checkpoint inhibition", Cancer Immunol Res, 3, pp.1115~1122 (2015)
9. Rosenberg SA, "Adoptive cell transfer as personalized immunotherapy for human cancer", Science, 348, pp.62~68 (2015)
10. Laskowski T, "Adoptive cell therapy : Living drugs against cancer", J Exp Med, 217, pp.e20200377~ (2020)
11. Rohaan MW, "Adoptive cellular therapies : the current landscape", Virchows Arch, 474, pp.449~461 (2019)
12. Kalluri R, "The biology, function, and biomedical applications of exosomes", Science, 367, pp.eaau6977~ (2020)
13. Zhang Y, "Exosomes : biogenesis, biologic function and clinical potential", Cell Biosci, 9, pp.19~ (2019)
14. Mathieu M, "Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication", Nat Cell Biol, 21, pp.9~17 (2019)
15. Fais S, "NK cell-released exosomes : natural nanobullets against tumors", Oncoimmunology, 2, pp.e22337~ (2013)
16. Pitt JM, "Dendritic cell-derived exosomes for cancer therapy", J Clin Invest, 126, pp.1224~1232 (2016)
17. Hong Y, "Degradation of tumour stromal hyaluronan by small extracellular vesiclePH20 stimulates CD103(+)dendritic cells and in combination with PD-L1 blockade boosts anti-tumour immunity", J Extracell Vesicles, 8, pp.1670893~ (2019)
18. Kim GB, "Xenogenization of tumor cells by fusogenic exosomes in tumor microenvironment ignites and propagates antitumor immunity", Sci Adv, 6, pp.eaaz2083~ (2020)
19. Koh E, "Exosome-SIRPalpha, a CD47 blockade increases cancer cell phagocytosis", Biomaterials, 121, pp.121~129 (2017)
20. Tran TH, "Exosomes as nanocarriers for immunotherapy of cancer and inflammatory diseases", Clin Immunol, 160, pp.46~58 (2015)
21. Yang Y, "Extracellular vesicles as a platform for membrane-associated therapeutic protein delivery", J Extracell Vesicles, 7, pp.1440131~ (2018)
22. Hong Y, "Exosome as a vehicle for delivery of membrane protein therapeutics, PH20, for enhanced tumor penetration and antitumor efficacy", Adv Funct Mater, 28, pp.1703074~ (2018)
23. Yang JC, "Adoptive T-cell therapy for cancer", Adv Immunol, 130, pp.279~294 (2016)
24. Dudley ME, "Adoptive-cell-transfer therapy for the treatment of patients with cancer", Nat Rev Cancer, 3, pp.666~675 (2003)
25. Rosenberg SA, "Use of tumor-infiltrating lymphocytes and interleukin-2in the immunotherapy of patients with metastatic melanoma. A preliminary report", N Engl J Med, 319, pp.1676~1680 (1988)
26. Ott PA, "An update on adoptive T-cell therapy and neoantigen vaccines", Am Soc Clin Oncol Educ Book, 39, pp.e70~ (2019)
27. Essand M, "Genetically engineered T cells for the treatment of cancer", J Intern Med, 273, pp.166~181 (2013)
28. Morgan RA, "Cancer regression in patients after transfer of genetically engineered lymphocytes", Science, 314, pp.126~129 (2006)
29. Johnson LA, "Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen", Blood, 114, pp.535~546 (2009)
30. Robbins PF, "Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1", J Clin Oncol, 29, pp.917~924 (2011)
31. Robbins PF, "A pilot trial using lymphocytes genetically engineered with an NYESO-1-reactive T-cell receptor : long-term follow-up and correlates with response", Clin Cancer Res, 21, pp.1019~1027 (2015)
32. Miliotou AN, "CAR T-cell therapy : a new era in cancer immunotherapy", Curr Pharm Biotechnol, 19, pp.5~18 (2018)
33. Feins S, "An introduction to chimeric antigen receptor(CAR)T-cell immunotherapy for human cancer", Am J Hematol, 94, pp.S3~ (2019)
34. Maude SL, "Chimeric antigen receptor T cells for sustained remissions in leukemia", N Engl J Med, 371, pp.1507~1517 (2014)
35. Schuster SJ, "Chimeric antigen receptor T cells in refractory B-cell lymphomas", N Engl J Med, 377, pp.2545~2554 (2017)
36. Alexander M, "Chimeric antigen receptor T-cell therapy : a comprehensive review of clinical efficacy, toxicity, and best practices for outpatient administration", Transplant Cell Ther, 27, pp.558~570 (2021)
37. Hu W, "cancer immunotherapy based on natural killer cells : current progress and new opportunities", Front Immunol, 10, pp.1205~ (2019)
38. Shimasaki N, "NK cells for cancer immunotherapy", Nat Rev Drug Discov, 19, pp.200~218 (2020)
39. Liu S, "NK cell-based cancer immunotherapy : from basic biology to clinical development", J Hematol Oncol, 14, pp.7~ (2021)
40. Klingemann H, "Natural killer cells for immunotherapy-advantages of the NK-92cell line over blood NK Cells", Front Immunol, 7, pp.91~ (2016)
41. Kundu S, "Generating natural killer cells for adoptive transfer : expanding horizons", Cytotherapy, 23, pp.559~566 (2021)
42. Bollino D, "Chimeric antigen receptor-engineered natural killer and natural killer T cells for cancer immunotherapy", Transl Res, 187, pp.32~43 (2017)
43. Tang X, "First-in-man clinical trial of CAR NK-92 cells : safety test of CD33-CAR NK-92cells in patients with relapsed and refractory acute myeloid leukemia", Am J Cancer Res, 8, pp.1083~1089 (2018)
44. Rapoport AP, "Rapid immune recovery and graft-versus-host disease-like engraftment syndrome following adoptive transfer of costimulated autologous T cells", Clin Cancer Res, 15, pp.4499~4507 (2009)
45. Magalhaes I, "Facing the future : challenges and opportunities in adoptive T cell therapy in cancer", Expert Opin Biol Ther, 19, pp.811~827 (2019)
46. Parkhurst MR, "T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis", Mol Ther, 19, pp.620~626 (2011)
47. Kochenderfer JN, "B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells", Blood, 119, pp.2709~2720 (2012)
48. Morgan RA, "Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2", Mol Ther, 18, pp.843~851 (2010)
49. Shimabukuro-Vornhagen A, "Cytokine release syndrome", J Immunother Cancer, 6, pp.56~ (2018)
50. Kochenderfer JN, "Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels", J Clin Oncol, 35, pp.1803~1813 (2017)
51. Neelapu SS, "Chimeric antigen receptor T-cell therapy-assessment and management of toxicities", Nat Rev Clin Oncol, 15, pp.47~62 (2018)
52. Bonifant CL, "Toxicity and management in CAR T-cell therapy", Mol Ther Oncolytics, 3, pp.16011~ (2016)
53. Khadka RH, "Management of cytokine release syndrome : an update on emerging antigen-specific T cell engaging immunotherapies", Immunotherapy, 11, pp.851~857 (2019)
54. Murthy H, "Cytokine release syndrome : current perspectives", Immunotargets Ther, 8, pp.43~52 (2019)
55. Tang H, "Immunotherapy and tumor microenvironment", Cancer Lett, 370, pp.85~90 (2016)
56. Beavis PA, "Reprogramming the tumor microenvironment to enhance adoptive cellular therapy", Semin Immunol, 28, pp.64~72 (2016)
57. Thommen DS, "T Cell dysfunction in cancer", Cancer Cell, 33, pp.547~562 (2018)
58. Slattery K, "NK cell metabolism and TGFbeta-implications for immunotherapy", Front Immunol, 10, pp.2915~ (2019)
59. Riggan L, "Arrested development : suppression of NK cell function in the tumor microenvironment", Clin Transl Immunology, 10, pp.e1238~ (2021)
60. Melaiu O, "Influence of the tumor microenvironment on NK cell function in solid tumors", Front Immunol, 10, pp.3038~ (2019)
61. Comoli P, "Development of adaptive immune effector therapies in solid tumors", Ann Oncol, 30, pp.1740~1750 (2019)
62. Thery C, "Exosomes : composition, biogenesis and function", Nat Rev Immunol, 2, pp.569~579 (2002)
63. Colombo M, "Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles", Annu Rev Cell Dev Biol, 30, pp.255~289 (2014)
64. Hessvik NP, "Current knowledge on exosome biogenesis and release", Cell Mol Life Sci, 75, pp.193~208 (2018)
65. Jeppesen DK, "Reassessment of exosome composition", Cell, 177, pp.428~445 (2019)
66. Thery C, "Membrane vesicles as conveyors of immune responses", Nat Rev Immunol, 9, pp.581~593 (2009)
67. Skotland T, "Lipids in exosomes : current knowledge and the way forward", Prog Lipid Res, 66, pp.30~41 (2017)
68. Bobrie A, "Exosome secretion : molecular mechanisms and roles in immune responses", Traffic, 12, pp.1659~1668 (2011)
69. Nam GH, "Emerging prospects of exosomes for cancer treatment : from conventional therapy to immunotherapy", Adv Mater, 32, pp.e2002440~ (2020)
70. Raposo G, "B lymphocytes secrete antigen-presenting vesicles", J Exp Med, 183, pp.1161~1172 (1996)
71. Li Q, "Exosomes : versatile nano mediators of immune regulation", Cancers(Basel), 11, pp.1557~ (2019)
72. Jankovicova J, "Tetraspanins, more than markers of extracellular vesicles in reproduction", Int J Mol Sci, 21, pp.7568~ (2020)
73. Nikfarjam S, "Dexosomes as a cell-free vaccine for cancer immunotherapy", J Exp Clin Cancer Res, 39, pp.258~ (2020)
74. Ventimiglia LN, "Biogenesis and function of T cell-derived exosomes", Front Cell Dev Biol, 4, pp.84~ (2016)
75. Ventimiglia LN, "Cutting edge : regulation of exosome secretion by the integral MAL protein in T cells", J Immunol, 195, pp.810~814 (2015)
76. Wahlgren J, "Activated human T cells secrete exosomes that participate in IL-2 mediated immune response signaling", PLoS One, 7, pp.e49723~ (2012)
77. Li L, "IL-12stimulates CTLs to secrete exosomes capable of activating bystander CD8(+)T cells", Sci Rep, 7, pp.13365~ (2017)
78. Mittelbrunn M, "Unidirectional transfer of microRNA-loaded exosomes from T cells to antigen-presenting cells", Nat Commun, 2, pp.282~ (2011)
79. Fu W, "CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity", Nat Commun, 10, pp.4355~ (2019)
80. Yang P, "The exosomes derived from CAR-T cell efficiently target mesothelin and reduce triple-negative breast cancer growth", Cell Immunol, 360, pp.104262~ (2021)
81. Lugini L, "Immune surveillance properties of human NK cell-derived exosomes", J Immunol, 189, pp.2833~2842 (2012)
82. Jong AY, "Large-scale isolation and cytotoxicity of extracellular vesicles derived from activated human natural killer cells", J Extracell Vesicles, 6, pp.1294368~ (2017)
83. Zhu L, "Exosomes derived from natural killer cells exert therapeutic effect in melanoma", Theranostics, 7, pp.2732~2745 (2017)
84. Shoae-Hassani A, "NK cell-derived exosomes from NK cells previously exposed to neuroblastoma cells augment the antitumor activity of cytokine-activated NK cells", J Immunother, 40, pp.265~276 (2017)
85. Di Pace AL, "Characterization of human NK cell-derived exosomes : Role of DNAM1receptor in exosome-mediated cytotoxicity against tumor", Cancers(Basel), 12, pp.661~ (2020)
86. Neviani P, "Natural killer-derived exosomal miR-186 inhibits neuroblastoma growth and immune escape mechanisms", Cancer Res, 79, pp.1151~1164 (2019)
87. Wculek SK, "Dendritic cells in cancer immunology and immunotherapy", Nat Rev Immunol, 20, pp.7~24 (2020)
88. Viaud S, "Dendritic cell-derived exosomes promote natural killer cell activation and proliferation : a role for NKG2D ligands and IL-15Ralpha", PLoS One, 4, pp.e4942~ (2009)
89. Munich S, "Dendritic cell exosomes directly kill tumor cells and activate natural killer cells via TNF superfamily ligands", Oncoimmunology, 1, pp.1074~1083 (2012)
90. Morse MA, "A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer", J Transl Med, 3, pp.9~ (2005)
91. Besse B, "Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC", Oncoimmunology, 5, pp.e1071008~ (2016)
92. Escudier B, "Vaccination of metastatic melanoma patients with autologous dendritic cell(DC)derived-exosomes : results of thefirst phase I clinical trial", J Transl Med, 3, pp.10~ (2005)
93. Dai S, "Phase I clinical trial of autologous ascites-derived exosomes combined with GM-CSF for colorectal cancer", Mol Ther, 16, pp.782~790 (2008)
94. Cheng L, "Exosomes from M1-polarized macrophages potentiate the cancer vaccine by creating a pro-inflammatory microenvironment in the lymph node", Mol Ther, 25, pp.1665~1675 (2017)
95. Wang P, "Exosomes from M1-polarized macrophages enhance paclitaxel antitumor activity by activating macrophages-mediated inflammation", Theranostics, 9, pp.1714~1727 (2019)
96. Li J, "M1 macrophage-derived exosome-encapsulated cisplatin can enhance its anti-lung cancer effect", Minerva Med (2020)
97. Zhang X, "The effects of umbilical cord-derived macrophage exosomes loaded with cisplatin on the growth and drug resistance of ovarian cancer cells", Drug Dev Ind Pharm, 46, pp.1150~1162 (2020)
98. Kim MS, "Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells", Nanomedicine, 12, pp.655~664 (2016)
99. Zhang Y, "Exosome : a review of its classification, isolation techniques, storage, diagnostic and targeted therapy applications", Int J Nanomedicine, 15, pp.6917~6934 (2020)
100. Tian Y, "A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy", Biomaterials, 35, pp.2383~2390 (2014)
101. Yang D, "Progress, opportunity, and perspective on exosome isolation-efforts for efficient exosome-based theranostics", Theranostics, 10, pp.3684~3707 (2020)
102. Busatto S, "Tangential flow filtration for highly efficient concentration of extracellular vesicles from large volumes of fluid", Cells, 7, pp.273~ (2018)
103. Chen YS, "Exosomes in clinical trial and their production in compliance with good manufacturing practice", Ci Ji Yi Xue Za Zhi, 32, pp.113~120 (2020)
104. Whitford W, "Exosome manufacturing status", Future Med Chem, 11, pp.1225~1236 (2019)

관련 논문AI추천